Publication Cover
Physiotherapy Theory and Practice
An International Journal of Physical Therapy
Volume 37, 2021 - Issue 12
272
Views
3
CrossRef citations to date
0
Altmetric
Research Report

Randomized feasibility study of twice a day functional electrostimulation in patients with severe chronic obstructive pulmonary disease hospitalized for acute exacerbation

, MSc, PT, , PhD, PT, , MSc, PT, , PhD, PT, , PhD, PT & , PhD, PT
Pages 1360-1367 | Received 27 Sep 2018, Accepted 15 Oct 2019, Published online: 26 Nov 2019
 

ABSTRACT

Introduction:Pulmonary rehabilitation is an effective intervention for individuals who have Chronic Obstructive Pulmonary Disease (COPD). The adequate intensity, components, and number of sessions are difficult to determine, specifically in patients who have severe ventilatory limitations in order to produce true physiological training effects without adverse events. Objective:Our aim is to assess the feasibility and possible effects of a daily versus a twice-daily functional electrostimulation program in hospitalized individuals who have a severe COPD. Methods:In this randomized controlled trial, 48 severe patients with COPD were randomized into three groups: Control Group (CG; n = 16), daily functional electrostimulation group (DFEG; n = 15) or twice-daily functional electrostimulation group (TFEG; n = 17). The main outcome measures were quadriceps strength, symptoms at rest and after exercise, and adverse events measured before and after the intervention. Results:After eight sessions, DFEG and TFEG showed significant differences when compared to the CG in all measured variables at discharge (p ≤ .001), no adverse events were observed in any of the treatment groups. Significant improvements were found in strength (p ≤ .05) between DFEG and TFEG groups. However, lower limb function did not present significant differences in spite of the fact that the mean change favored the TFEG (23.53 ± 3.53 vs. 19.56 ± 11.89). Conclusion:Further examination of twice per day functional electrostimulation in hospitalized patients with COPD with acute exacerbation appears warranted.

Acknowledgments

This work was financed jointly by Fundación Progreso y Salud (FPS) and Boehringer Ingelheim España, SA. Project code: PI-0370-2014. Oximesa, Praxair.

Disclosure statement

The authors declare that there are no conflicts of interest.

Additional information

Funding

This work was supported by the FPU (‘Formación Profesorado Universitario’) grant (FPU: 17/00408) of the Spanish Ministry of Education.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.